Vanguard Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.63M Sell
731,391
-4,456
-0.6% -$19.7K ﹤0.01% 3287
2026
Q2
$4.34M Buy
735,847
+198,686
+37% +$981K ﹤0.01% 3174
2026
Q1
$1.76M Buy
+537,161
New +$3.12M ﹤0.01% 3404

Other funds holding IMDX

Vanguard Capital Management's IMDX Position: Q3 2026 in Review

Vanguard Capital Management reduced its Insight Molecular Diagnostics (IMDX) stake by 0.61% in Q3 2026, selling an estimated $19.7K and leaving 731,391 shares worth $2.63M. The position accounts for ﹤0.01% of the portfolio, ranked #3287.

Vanguard Capital Management first reported a position in IMDX in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.34M in Q2 2026. 40 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.

  • Vanguard Capital Management held 731,391 shares of Insight Molecular Diagnostics worth $2.63M as of Q3 2026.
  • Vanguard Capital Management sold 4,456 Insight Molecular Diagnostics shares in Q3 2026, an estimated $19.7K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3287 holding.
  • Vanguard Capital Management first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Insight Molecular Diagnostics position peaked at $4.34M in Q2 2026.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.